CoChat

Searching for Disease Modifiers—PKC Activation and HDAC Inhibition—A Dual Drug Approach to Alzheimer's Disease that Decreases Aβ Production while Blocking Oxidative Stress

Open access
Kozikowski, Alan P., Chen, Yihua, Subhasish, Tapadar, Lewin, Nancy E., Blumberg, Peter M., Zhong, Zhenyu, D'Annibale, Melissa A., Wang, Weng‐Long, Shen, Yong, Langley, Brett · 2009 · ChemMedChem
Cited by 44

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

A series of benzolactam compounds were synthesized, some of which caused a concentration‐dependent increase in sAPPα and decrease in Aβ production in the concentration range of 0.1–10 μ M. Moreover, some compounds showed neuroprotective effects in the 10–20 μ M range in the HCA cortical neuron model of oxidative stress and no toxicity in measurements of neuron viability by MTT assay, even at the highest concentrations tested (20 μ M).magnified image Alzheimer's disease (AD) is a well‐studied neurodegenerative process characterized by the presence of amyloid plaques and neurofibrillary tangles. In this study, a series of protein kinase C (PKC) activators were investigated, some of which also exhibit histone deacetylase (HDAC) inhibitory activity, under the hypothesis that such compounds might provide a new path forward in the discovery of drugs for the treatment of AD. The PKC‐activating properties of these drugs were expected to enhance the α‐secretase pathway in the processing of amyloid precursor protein (APP), while their HDAC inhibition was anticipated to confer neuroprotective activity. We found that benzolactams 9 and 11–14 caused a concentration‐dependent increase in sAPPα and decrease in β‐amyloid (Aβ) production in the concentration range of 0.1–10 μ M, consistent with a shift of APP metabolism toward the α‐secretase‐processing pathway. Moreover, compounds 9–14 showed neuroprotective effects in the 10–20 μ M range in the homocysteate (HCA) cortical neuron model of oxidative stress. In parallel, we found that the most neuroprotective compounds caused increased levels of histone acetylation (H4), thus indicating their likely ability to inhibit HDAC activity. As the majority of the compounds studied also show nanomolar binding affinities for PKC, we conclude that it is possible to design, de novo, agents that combine both PKC‐activating properties along with HDAC inhibitory properties. Such agents would be capable of modulating amyloid processing while showing neuroprotection. These findings may offer a new approach to therapies that exhibit disease‐modifying effects, as opposed to symptomatic relief, in the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cmdc.200900045

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

Metadata

Authors
Kozikowski, A. P., Chen, Y., Subhasish, T., Lewin, N. E., Blumberg, P. M., Zhong, Z., D'Annibale, M. A., Wang, W., Shen, Y., & Langley, B.
Venue
ChemMedChem
Publisher
Wiley
Published
2009-06-29
Volume
4
Issue
7
Pages
1095-1105
ISSN
  • 1860-7179 (ISSN-L)
  • 1860-7187
OpenAlex
W2021471758
Cited by
44
References
11
FWCI
2.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.